Jamie Carr Columnist

Big Tobacco has been walking around with a whacking great target on its back ever since the medical fraternity first suggested that puffing away on 40 gaspers a day may not be the best possible thing for your health. While litigation has failed to kill it off — and it has continued to print money in the intervening period — it is looking increasingly nervous at the approach of the disrupters, who have created a product that dishes up the nicotine fix without, they say, the downside of early and painful death. The big players have been investing heavily in next-generation products, but they have been roundly outplayed by the arrival of Juul, which has captured 70% of the US vaping market since it launched in 2015. It has now started to roll out into other markets, including the UK and Israel. Juul’s success is based on a combination of sleek design, a strong social media presence, celebrity endorsers and the fact that at 5% nicotine concentration, its pods deliver a kick like a parti...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now